Cordlife Group Ltd represents a commitment to providing advanced cord blood and tissue banking services. Their corporate philosophy revolves around prioritizing the healthcare needs of families. Cordlife aims to offer secure storage for umbilical cord blood, which contains valuable stem cells that have potential therapeutic applications. They believe in empowering individuals and the medical community with access to these life-saving resources, helping to pave the way for advancements in regenerative medicine. Cordlife Group Ltd recognizes the importance of investing in technology and research to continually improve their services and contribute to the field of stem cell science.

Cordlife Group Ltd is primarily present in several countries and regions. The company has a strong presence in Singapore, where it is headquartered. It is also actively operating in Hong Kong, India, Indonesia, Malaysia, and the Philippines. Cordlife Group Ltd has established cord blood banks and stem cell facilities in these countries, offering various services and products related to cord blood banking and umbilical cord stem cell preservation. With its extensive network and expertise, Cordlife Group Ltd continues to expand and provide reliable services to families seeking to store their newborn's cord blood for future medical use.

Cordlife Group Ltd has achieved several significant milestones in its history. One of the notable achievements was the successful IPO listing on the Singapore Exchange Securities Trading Limited in 2011. This milestone not only demonstrated the company's strong market position but also opened up new opportunities for growth and expansion. Furthermore, Cordlife Group Ltd has consistently expanded its presence in the international market, establishing a strong foothold in countries like Hong Kong, India, and the Philippines. Additionally, the company has received several prestigious awards and recognition for its commitment to quality and excellence in stem cell banking services. These achievements have solidified Cordlife Group Ltd's position as a leading player in the industry.

Cordlife Group Ltd is a leading consumer healthcare group, dedicated to providing stem cell banking and cord blood services. Founded in 2001, Cordlife has a rich history of delivering high-quality stem cell banking solutions to families in Asia-Pacific. With a strong focus on innovation and research, Cordlife has established a reputation for its state-of-the-art laboratory facilities and commitment to exceptional service. As a pioneer in the field, Cordlife has successfully stored and preserved thousands of cord blood units, offering opportunities for future medical treatments and therapies. With a strong track record and a dedicated team of professionals, Cordlife Group Ltd continues to pave the way in the stem cell banking industry.

The main competitors of Cordlife Group Ltd in the market are StemLife, Cryoviva, and Cryo-Save.

Cordlife Group Ltd is primarily active in the healthcare industry.

Cordlife Group Ltd operates with a business model focused on providing cord blood banking and cord tissue banking services. As a leading consumer healthcare company, Cordlife Group offers expectant parents the opportunity to store their baby's umbilical cord blood and tissue, which contain potentially life-saving stem cells. These stem cells can be used in the future for various medical treatments, including cancer, blood disorders, and immune system disorders. Cordlife Group ensures that the collected stem cells are processed, tested, and stored under strict quality standards, ensuring their viability and safety for potential future use.

De K/W-verhouding kan momenteel niet worden berekend voor Cordlife Group.

De KUV kan momenteel niet worden berekend voor Cordlife Group.

De AlleAktien Kwaliteitsscore voor Cordlife Group is 2/10.

De omzet kan momenteel niet worden berekend voor Cordlife Group.

De winst kan momenteel niet berekend worden voor Cordlife Group.

Cordlife Group Ltd is a biotechnology company specializing in stem cell storage. The company offers various products and services tailored to the needs of families and medical professionals. Cordlife operates stem cell storage banks in various countries, including Australia, Hong Kong, India, Indonesia, Malaysia, Philippines, Singapore, and Thailand. The facilities are certified to the highest international quality standards and provide a safe and reliable solution for stem cell storage. The company offers various stem cell products, including umbilical cord blood, umbilical cord tissue, and placental tissue. These products can be used for various diseases and conditions, such as leukemia, sickle cell anemia, thalassemia, autism, cerebral palsy, and diabetes. Cordlife also offers services for the collection of umbilical cord blood and umbilical cord tissue. The company works with selected medical facilities to ensure safe and effective collection. Umbilical cord blood collection is a simple and non-invasive method that can be done during childbirth. Cordlife also has a research and development department focused on the development of new technologies and products. The company strives to constantly improve its services and provide innovative solutions to enhance the health and well-being of people worldwide. The business model of Cordlife Group Ltd is based on stem cell storage and providing products and services tailored to the needs of families and medical professionals. The company utilizes state-of-the-art technologies and facilities to ensure safe and effective storage and collection of stem cells. The company has a strong focus on research and development of new technologies and products to ensure it stays at the forefront of science. This allows the company to improve its services and offer innovative solutions to enhance the health and well-being of people worldwide. Cordlife Group Ltd has a strong presence in Asia and is constantly expanding into new regions and countries. The company works closely with medical facilities and professionals to continuously improve and optimize its services. In conclusion, Cordlife Group Ltd is a biotechnology company specializing in stem cell storage and provision of stem cell products and services. The company has a strong focus on research and development of new technologies and products to ensure it stays at the forefront of science. With its strong emphasis on quality and customer service, Cordlife Group Ltd is expected to remain a leading player in the biotechnology industry.

Cordlife Group keert een dividend van 0,01 SGD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Cordlife Group of het bedrijf keert geen dividend uit.

De ISIN van Cordlife Group is SG2E64980112.

Het WKN van Cordlife Group is A1JWVR.

De ticker van Cordlife Group is P8A.SI.

Binnen de laatste 12 maanden betaalde Cordlife Group een dividend van 0,01 SGD . Dit komt overeen met een dividendrendement van ongeveer 6,00 %. Voor de komende 12 maanden zal Cordlife Group naar verwachting een dividend van 0,01 SGD betalen.

De dividendrendement van Cordlife Group is momenteel 6,00 %.

Cordlife Group betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden mei, juli, juni, juni.

Cordlife Group betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0,01 SGD verwacht. Dit komt overeen met een dividendrendement van 6,00 %.

Cordlife Group wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Cordlife Group van 27-5-2022 ter hoogte van 0,009 SGD te ontvangen, moest je het aandeel voor de ex-datum op 6-5-2022 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 27-5-2022.

In het jaar 2023 heeft Cordlife Group 0,009 SGD aan dividenden uitgekeerd.

De dividenden van Cordlife Group worden in SGD uitgekeerd.